In this sense, our hypothesis is that sotalol (a peripheral non-selective β-ARs blocker) (Martinho et al., 2022) and nepicastat (a DBH inhibitor) (Martinho et al., 2021; Moreira-Rodrigues and Grubisha, 2022; Abumaria et al., 2023) might help to decrease PTSD occurrence by weakening abnormal traumatic memories formation and consolidation, and may support in the formation of neutral contextual memories. The gene discussed is CTBP1; the disease is post-traumatic stress disorder.